Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Genecast (Beijing) and US-based Interpace Form Diagnostics Partnership

publication date: Sep 17, 2019

Genecast (Beijing) Biotech, a cancer diagnostics company, partnered with Interpace Diagnostics of New Jersey to offer translational studies and clinical trial diagnostics to biopharma companies. According to the agreement, Interpace will offer the diagnostic products/services worldwide except in China, where Genecast will be responsible for them. Founded in 2014, Genecast has developed circulating tumor DNA (ctDNA) detection technology that provides individualized cancer diagnoses. In 2017, the company raised $18 million in a Series B round led by Tshinghua Holdings. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China